The day Sanofi has dreaded is coming. Novo Nordisk ($NVO) won European backing for its new insulin, Tresiba, the drug that could become Lantus' nemesis. If Tresiba ...
As a major medical meeting brings the spotlight to new diabetes drugs this month, Sanofi ($SNY) has begun reaching out to the media to secure center-stage status for ...
The dosage of Lantus is individualized and depends on several factors, such as the type of diabetes being treated, your body weight, blood sugar goals, and response to treatment. Lantus is given as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results